Quantitative analysis of HER2 receptor expression in vivo by near-infrared optical imaging

Molecular Imaging

Volumn 9, Issue 4, 2010, Pages 192-200

  Chernomordik, Victor ^a,b   Hassan, Moinuddin ^a,b   Lee, Sang Bong ^a,b   Zielinski, Rafal ^a,b   Gandjbakhche, Amir ^a,b,c   Capala, Jacek ^a,b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFFIBODY MOLECULES; ALEXA FLUOR; BINDING DOMAIN; BREAST CANCER; CURRENT TECHNIQUES; ENZYME LINKED IMMUNOSORBENT ASSAY; EX-VIVO; EXPERIMENTAL DATA; FLUORESCENCE INTENSITIES; HUMAN EPIDERMAL GROWTH FACTOR; IMAGING DATA; IN-VIVO; LIGAND-RECEPTOR; MATHEMATICAL MODELING; MOLECULAR PROBES; NEAR-INFRARED FLUORESCENCE; NEAR-INFRARED OPTICAL IMAGING; NON-INVASIVE MONITORING; NONINVASIVE METHODS; OPTICAL IMAGE; OPTICAL IMAGING; OVER-EXPRESSION; POSTINJECTION; QUANTITATIVE ANALYSIS; RECEPTOR EXPRESSION; SMALL ANIMAL IMAGING; SUBCUTANEOUS TUMOR; TEMPORAL DEPENDENCE; TISSUE BIOPSIES; TUMOR CELLS;

ASSAYS; BIOLOGICAL MATERIALS; FLUORESCENCE; GEOMETRICAL OPTICS; INFRARED DEVICES; OPTICAL CORRELATION; OPTICAL IMAGE STORAGE; PROBES;

TUMORS;

ALEXA FLUOR 750; ANTIBODY CONJUGATE; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORESCENT DYE; HER2 PROTEIN, HUMAN; HYBRID PROTEIN; SUCCINIMIDE DERIVATIVE;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; BIOSYNTHESIS; BREAST TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; GENE EXPRESSION; HUMAN; METHODOLOGY; MOUSE; NEAR INFRARED SPECTROSCOPY; NUDE MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT DYES; GENE EXPRESSION; HUMANS; IMMUNOCONJUGATES; MICE; MICE, NUDE; MODELS, BIOLOGICAL; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SPECTROSCOPY, NEAR-INFRARED; SUCCINIMIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 77956492439     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2010.00018     Document Type: Article

References (29)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
2. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006;232:123-38.
3. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54.
4. Kobayashi H, Shirakawa K, Kawamoto S, et al. Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256). Cancer Res 2002;62:860-6.
5. Lub-de Hooge MN, Kosterink JG, Perik PJ, et al. Preclinical characterisation of 111in-DTPA-trastuzumab. Br J Pharmacol 2004;143:99-106.
6. Milenic DE, Garmestani K, Brady ED, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004;10:7834-41.
7. Smith-Jones PM, Solit DB, Akhurst T, et al. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701-6.
8. Lee SB, Hassan M, Fisher R, et al. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res 2008;14:3840-9.
9. Orlova A, Tolmachev V, Pehrson R, et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 2007;67:2178-86.
10. Tolmachev V, Nilsson FY, Widstrom C, et al. 111In-benzyl-DTPA-ZHER2:342, an Affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 2006;47:846-53.
11. Cheng Z, De Jesus OP, Namavari M, et al. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 2008;49:804-13.
12. Kramer-Marek G, Kiesewetter DO, Martiniova L, et al. [18F]FBEM- Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008;35:1008-18.
13. Chen Y, Zheng G, Zhang ZH, et al. Metabolism-enhanced tumor localization by fluorescence imaging: in vivo animal studies. Opt Lett 2003;28:2070-72.
14. Rinneberg H, Grosenick D, Moesta KT, et al. Scanning time- domain optical mammography: detection and characterization of breast tumors in vivo. Technol Cancer Res Treat 2005;4:483-96.
15. Becker A, Hessenius C, Licha K, et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol 2001;19:327-31.
16. Bugaj JE, Achilefu S, Dorshow RB, et al. Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor- targeted dye-peptide conjugate platform. J Biomed Opt 2001;6: 122-33.
17. Engelbrecht CJ, Johnston RS, Seibel EJ, et al. Ultra-compact fiberoptic two-photon microscope for functional fluorescence imaging in vivo. Opt Express 2008;16:5556-64.
18. Masotti A, Vicennati P, Boschi F, et al. A novel near-infrared indocyanine dye-polyethylenimine conjugate allows DNA delivery imaging in vivo. Bioconjug Chem 2008;19:983-7.
19. Mitra S, Foster TH. In vivo confocal fluorescence imaging of the intratumor distribution of the photosensitizer mono-L-aspartyl- chlorin-eNeoplasia 2008;10:429-38.
20. Hassan M, Riley J, Chernomordik V, et al. Fluorescence lifetime imaging system for in vivo studies. Mol Imaging 2007;6:229-36.
21. Delforge J, Mesangeau D, Dolle F, et al. In vivo quantification and parametric images of the cardiac beta-adrenergic receptor density. J Nucl Med 2002;43:215-26.
22. Pegram MD, Konecny GE, O'Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739- 49.
23. Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A 1992;89:5321-5.
24. Dierkes T, Grosenick D, Moesta KT, et al. Reconstruction of optical properties of phantom and breast lesion in vivo from paraxial scanning data. Phys Med Biol 2005;50:2519-2.
25. Grosenick D, Moesta KT, Moller M, et al. Time-domain scanning optical mammography: I. Recording and assessment of mammo- grams of 154 patients. Phys Med Biol 2005;50:2429-49.
26. Grosenick D, Moesta KT, Wabnitz H, et al. Time-domain optical mammography: initial clinical results on detection and characterization of breast tumors. Appl Opt 2003;42:3170-86.
27. Grosenick D, Wabnitz H, Moesta KT, et al. Concentration and oxygen saturation of haemoglobin of 50 breast tumours determined by time-domain optical mammography. Phys Med Biol 2004;49:1165-81.
28. Ntziachristos V, Yodh AG, Schnall M, et al. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci U S A 2000;97:2767-72.
29. Rinneberg H, Grosenick D, Moesta KT, et al. Detection and characterization of breast tumours by time-domain scanning optical mammography. Opto-Electronics Rev 2008;16:147-62.